Abstract

Simple SummaryAltered extracellular chondroitin sulfate (CS) contributes to tumor progression in many cancers. CHPF is a key enzyme supporting the elongation of CS. Here we showed that CHPF was frequently downregulated in hepatocellular carcinoma (HCC) tumors compared with adjacent non-tumor tissues, and its downregulation was associated with poor overall survival. CHPF regulated aggressive phenotypes of HCC cells in vitro and in vivo, and the TGF-β pathway involved in the phenotypical changes. Mechanistically, CHPF modified CS on decorin (DCN), which could facilitate DCN accumulation surrounding HCC cells, and modulate activation of TGF-β pathway. Indeed, the expression of DCN were positively associated with CHPF levels in primary HCC tissue. The research proposed novel insights into the significance of CHPF, which modified DCN and modulated TGF-β signaling.Aberrant composition of glycans in the tumor microenvironment (TME) and abnormal expression of extracellular matrix proteins are hallmarks of hepatocellular carcinoma (HCC); however, the mechanisms responsible for establishing the TME remain unclear. We demonstrate that the chondroitin polymerizing factor (CHPF), an enzyme that mediates the elongation of chondroitin sulfate (CS), is a critical elicitor of the malignant characteristics of HCC as it modifies the potent tumor suppressor, decorin (DCN). CHPF expression is frequently downregulated in HCC tumors, which is associated with the poor overall survival of HCC patients. We observed that restoring CHPF expression suppressed HCC cell growth, migration, and invasion in vitro and in vivo. Mechanistic investigations revealed that TGF-β signaling is associated with CHPF-induced phenotype changes. We found that DCN, as a TGF-β regulator, is modified by CHPF, and that it affects the distribution of DCN on the surface of HCC cells. Importantly, our results confirm that CHPF and DCN expression levels are positively correlated in primary HCC tissues. Taken together, our results suggest that CHPF dysregulation contributes to the malignancy of HCC cells, and our study provides novel insights into the significance of CS, which affects DCN expression in the TME.

Highlights

  • Hepatocellular carcinoma (HCC) occurs in 90.73% of men and 85.42% of women suffering from liver cancer; it is the third-leading cause of cancer-related deaths worldwide [1].Surgical resection, transarterial chemoembolization, radiofrequency ablation, and liver transplantation are the common hepatocellular carcinoma (HCC) treatment options; these approaches are only applicable in 30% of patients, and up to 50% of patients show relapse [2]

  • The results indicated that chondroitin polymerizing factor (CHPF) was downregulated in HCC tissues compared to non-tumor liver specimens

  • Our results suggest that CHPF is frequently downregulated in HCC, and that this downregulation is associated with advanced tumor stages and poor survival chances in HCC patients

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) occurs in 90.73% of men and 85.42% of women suffering from liver cancer; it is the third-leading cause of cancer-related deaths worldwide [1].Surgical resection, transarterial chemoembolization, radiofrequency ablation, and liver transplantation are the common HCC treatment options; these approaches are only applicable in 30% of patients, and up to 50% of patients show relapse [2]. Accumulating evidence suggests that changes in stromal cells, immune cells, extracellular proteins, and glycosylation status establish a tumor microenvironment (TME) that facilitates HCC progression [3,4,5,6,7]. Glycosaminoglycans (GAGs), which are unbranched polysaccharide chains in the extracellular matrix and on the cell surface, participate in various biological interactions with the TME. GAGs that covalently link to core proteins are known as proteoglycans (PGs), and certain types of GAGs such as hyaluronan occur as free chains. Recent studies have suggested that aberrant GAGs frequently accumulate in the TME of HCCs, and that may be correlated with disease progression. Proteases, cytokines, chemokines, and adhesion molecules have been found to interact with CS chains; the importance of CS chains in disease progression has been reevaluated [11,12,13,14,15]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call